Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL

Key Points HTS identifies MRD at the conventional clinical cutoff in more patients than FC, and these patients have worse outcomes. A subset of B-ALL patients essentially cured using current chemotherapy is identified at end of induction by HTS.